Distribuzione geografica
Continente #
NA - Nord America 4.739
EU - Europa 2.060
AS - Asia 451
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 5
Totale 7.260
Nazione #
US - Stati Uniti d'America 4.734
UA - Ucraina 416
IT - Italia 374
IE - Irlanda 362
SE - Svezia 303
DE - Germania 187
TR - Turchia 185
DK - Danimarca 152
FI - Finlandia 104
SG - Singapore 94
GB - Regno Unito 89
KR - Corea 80
CN - Cina 58
BE - Belgio 53
IN - India 24
FR - Francia 9
JP - Giappone 8
CA - Canada 5
EU - Europa 5
DZ - Algeria 3
NL - Olanda 3
AT - Austria 2
RO - Romania 2
CI - Costa d'Avorio 1
EG - Egitto 1
HR - Croazia 1
IR - Iran 1
MK - Macedonia 1
RS - Serbia 1
RU - Federazione Russa 1
TW - Taiwan 1
Totale 7.260
Città #
Chandler 629
Fairfield 497
Jacksonville 468
Dublin 356
Ashburn 351
Des Moines 349
Wilmington 259
Woodbridge 227
New York 194
Seattle 189
Houston 175
Ann Arbor 159
Cambridge 149
Lawrence 114
Princeton 114
Centro 105
Boardman 104
San Mateo 104
Turin 65
Brussels 52
San Diego 48
Beijing 44
Washington 29
Helsinki 27
London 27
Pune 23
Ancona 17
Norwalk 12
Izmir 10
Kilburn 9
Cupra Marittima 8
New Bedfont 8
Hounslow 6
Prescot 6
Redmond 6
Boydton 5
Kagoya 5
Toronto 5
Acton 4
Cagliari 4
Chiswick 4
Fermignano 4
Redwood City 4
Amsterdam 3
Falconara Marittima 3
Islington 3
Laurel 3
Porto 3
Rome 3
Santa Clara 3
Torre Del Greco 3
Castelraimondo 2
Citta 2
Civitanova Marche 2
Como 2
Fabriano 2
Isola della Scala 2
Marche 2
Milan 2
Modena 2
Montesilvano 2
Sassari 2
Shenzhen 2
Tolentino 2
Venice 2
Vienna 2
Wandsworth 2
Abidjan 1
Acerra 1
Andover 1
Ascoli Piceno 1
Belgrade 1
Campogalliano 1
Cedar Knolls 1
Chicago 1
Clearwater 1
Duncan 1
Falkenstein 1
Florence 1
Giza 1
Greenwich 1
Guangzhou 1
Hanover 1
Hebei 1
Matelica 1
Mondolfo 1
Nanjing 1
Nanning 1
New Delhi 1
Pesaro 1
Philadelphia 1
Phoenix 1
Quzhou 1
San Benedetto Del Tronto 1
San Francisco 1
San Giuliano 1
Seelze 1
Seoul 1
Skopje 1
Somerville 1
Totale 5.064
Nome #
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 128
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 113
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 107
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 104
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 98
Optimal management of resected gastric cancer 98
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 97
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 95
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 93
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 88
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 86
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 85
Adjuvant treatment after surgical resection 85
5-Fluorouracil pharmacogenomics: still rocking after all these years? 82
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 81
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 80
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 80
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 80
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 79
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 79
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 79
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 78
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 76
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 76
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 76
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 76
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 75
BRAF-mutant colorectal cancer, a different breed evolving 75
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 74
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 74
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 74
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 73
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 73
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 73
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 73
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan 71
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 71
Benefits and limitations of a multidisciplinary approach in cancer patient management 71
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 71
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 70
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 70
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 70
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 69
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 69
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 69
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 68
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 65
Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy 65
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 64
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase 64
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 64
Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: biological and clinical implications 63
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 63
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 63
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 62
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 62
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 62
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 62
Trattamento del carcinoma del pancreas. Attualità e prospettive 62
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 62
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 62
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 62
Panitumumab for the treatment of metastatic colorectal cancer: A review 61
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab 60
Gastric cancer: Therapeutic choices in advanced disease 60
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 60
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 59
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 59
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 58
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 58
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 57
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 57
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 56
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 56
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study 56
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 55
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 55
Selecting the best treatment for an individual patient. 55
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy 55
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 54
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 54
Maintenance therapy for metastatic colorectal cancer 54
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 54
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 53
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 53
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study 53
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 53
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 53
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib 52
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 52
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 52
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 52
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. 52
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 51
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 51
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 50
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 50
Identificazione di markers prognostici in pazienti con carcinoma colo-rettale metastatico trattati con Regorafenib 48
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 47
Totale 6.826
Categoria #
all - tutte 36.041
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.041

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201957 0 0 0 0 0 0 0 24 3 6 7 17
2019/2020574 0 6 73 2 95 1 94 8 91 15 35 154
2020/20211.804 109 173 216 101 249 121 108 135 142 197 150 103
2021/2022903 74 200 20 19 6 60 34 58 62 112 98 160
2022/20232.139 133 250 137 143 121 513 4 106 462 27 202 41
2023/20241.048 195 31 104 134 216 319 12 37 0 0 0 0
Totale 7.473